Favipiravir In India: Approved, Competition But What is Real Efficacy?

Favipiravir Approved to Target Mild to Moderate COVID-19 Patients in India & ‘Bare Knuckle’ Competition Ensues But Does it Work

Antiviral medication Favipiravir has been approved as a treatment for COVID-19 in Russia, China and India, not to mention Bangladesh and other nations. Now yet another generic version of the drug that originates in Japan (Avigan) has been announced by Indian generic drug company Optimus Pharma. Branded as Favicovid, it will compete against Glenmark’s FabiFlu generic version of Favipiravir and others. A handful of clinical trials in the United States are testing the antiviral, including Stanford University. Moreover, the U.S. Department of Defense (DOD) spent over $200 million on clinical trials investigating Favipiravir just five years ago. Yet few in America have ever head of this drug.


As reported in The Hindu, Optimus initiated work on Favipiravir quite early in the pandemic back in January, as it was reported the drug, in-vitro, was active against SARS-CoV-2. TrialSite has reported extensively on the Favipiravir story. Originally developed in Japan by Fujifilm Toyama Chemical Co. and known as Avigan, the drug was approved in Japan in 2014 for influenza. It became generic in 2019. TrialSite has reported that the drug is approved in China and Russia known as Avi...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee